VIRX
Price:
$0.2
Market Cap:
$7.88M
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and...[Read more]
Industry
Biotechnology
IPO Date
2005-09-27
Stock Exchange
NASDAQ
Ticker
VIRX
According to Viracta Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -292.12%. This represents a change of 105.84% compared to the average of -141.91% of the last 4 quarters.
The mean historical ROE of Viracta Therapeutics, Inc. over the last ten years is -208.84%. The current -292.12% ROE has changed 39.88% with respect to the historical average. Over the past ten years (40 quarters), VIRX's ROE was at its highest in in the December 2020 quarter at 13.60%. The ROE was at its lowest in in the September 2014 quarter at -434.74%.
Average
-208.84%
Median
-172.72%
Minimum
-666.54%
Maximum
41.56%
Discovering the peaks and valleys of Viracta Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 304.99%
Maximum Annual ROE = 41.56%
Minimum Annual Increase = -617.79%
Minimum Annual ROE = -666.54%
Year | ROE | Change |
---|---|---|
2023 | -278.72% | 242.15% |
2022 | -81.46% | -62.14% |
2021 | -215.17% | -617.79% |
2020 | 41.56% | -149.06% |
2019 | -84.70% | -87.29% |
2018 | -666.54% | 304.99% |
2017 | -164.58% | -9.00% |
2016 | -180.86% | 35.08% |
2015 | -133.89% | -58.68% |
2014 | -324.02% | -153.41% |
The current ROE of Viracta Therapeutics, Inc. (VIRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-191.78%
5-year avg
-123.70%
10-year avg
-208.84%
Viracta Therapeutics, Inc.’s ROE is greater than Vincerx Pharma, Inc. (-276.65%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), greater than Rallybio Corporation (-74.08%), greater than Tenaya Therapeutics, Inc. (-80.97%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Trevi Therapeutics, Inc. (-49.92%), greater than SQZ Biotechnologies Company (-10.98%), greater than Protara Therapeutics, Inc. (-55.03%), greater than ALX Oncology Holdings Inc. (-946.88%), greater than Cabaletta Bio, Inc. (-43.98%), greater than EyePoint Pharmaceuticals, Inc. (-43.24%), greater than Biomea Fusion, Inc. (-118.90%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Mereo BioPharma Group plc (-63.39%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Leap Therapeutics, Inc. (-98.01%), greater than Bicycle Therapeutics plc (-27.35%), greater than IGM Biosciences, Inc. (-119.02%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Stoke Therapeutics, Inc. (-57.89%),
Company | ROE | Market cap |
---|---|---|
-276.65% | $11.06M | |
-237.65% | $136.30K | |
-74.08% | $42.32M | |
-80.97% | $190.12M | |
-143.74% | $17.21M | |
-49.92% | $220.68M | |
-10.98% | $12.83M | |
-55.03% | $53.43M | |
-946.88% | $78.48M | |
-43.98% | $195.39M | |
-43.24% | $775.07M | |
-118.90% | $320.35M | |
32.93% | $89.59M | |
-63.39% | $616.59M | |
-68.93% | $277.29M | |
-39.58% | $599.50M | |
-98.01% | $140.43M | |
-27.35% | $1.62B | |
-119.02% | $930.71M | |
-70.40% | $542.54M | |
-57.89% | $689.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viracta Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Viracta Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Viracta Therapeutics, Inc.'s ROE?
How is the ROE calculated for Viracta Therapeutics, Inc. (VIRX)?
What is the highest ROE for Viracta Therapeutics, Inc. (VIRX)?
What is the 3-year average ROE for Viracta Therapeutics, Inc. (VIRX)?
What is the 5-year average ROE for Viracta Therapeutics, Inc. (VIRX)?
How does the current ROE for Viracta Therapeutics, Inc. (VIRX) compare to its historical average?